Suppr超能文献

KIF14 通过激活 Akt 促进细胞增殖,并且在结直肠癌中直接靶向 miR-200c。

KIF14 promotes cell proliferation via activation of Akt and is directly targeted by miR-200c in colorectal cancer.

机构信息

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Gastrointestinal Surgery IV, Peking University Cancer Hospital and Institute, Beijing 100142, P.R. China.

出版信息

Int J Oncol. 2018 Nov;53(5):1939-1952. doi: 10.3892/ijo.2018.4546. Epub 2018 Aug 29.

Abstract

As a mitotic kinesin, kinesin family member 14 (KIF14) has been reported to serve oncogenic roles in a variety of malignancies; however, its functional role and regulatory mechanisms in colorectal cancer (CRC) remain unclear. In the present study, KIF14 was observed to be markedly overexpressed in CRC, and this upregulation was associated with tumor size and marker of proliferation Ki-67 immunostaining scores. Gain- and loss-of-function experiments were applied to identify the function of KIF14 in CRC progression. In vitro and in vivo assays revealed that KIF14 promoted CRC cell proliferation and accelerated the cell cycle via activation of protein kinase B. In addition, the present study investigated the potential mechanisms underlying KIF14 overexpression in CRC. Bioinformatics analyses and validation experiments, including reverse transcription-quantitative polymerase chain reaction, western blotting and a Dual-Luciferase reporter assay, demonstrated that, in addition to genomic amplification and transcriptional activation, KIF14 was regulated by microRNA (miR)-200c at the post-transcriptional level. Rescue experiments further demonstrated that decreased miR-200c expression could facilitate KIF14 to exert its pro-proliferative role. The expression of miR-200c was negatively correlated with KIF14 in CRC specimens. Collectively, the findings of the present study demonstrated the oncogenic role of KIF14 in colorectal tumorigenesis, and also revealed a complexity of regulatory mechanisms mediating KIF14 overexpression, which may provide insight for developing novel treatments for patients with CRC.

摘要

作为一个有丝分裂驱动蛋白,驱动蛋白家族成员 14(KIF14)已被报道在多种恶性肿瘤中发挥致癌作用;然而,其在结直肠癌(CRC)中的功能作用和调节机制尚不清楚。在本研究中,观察到 KIF14 在 CRC 中明显过表达,这种上调与肿瘤大小和增殖标志物 Ki-67 免疫染色评分相关。通过增益和缺失功能实验来确定 KIF14 在 CRC 进展中的作用。体外和体内实验表明,KIF14 通过激活蛋白激酶 B 促进 CRC 细胞增殖并加速细胞周期。此外,本研究还探讨了 KIF14 在 CRC 中过表达的潜在机制。生物信息学分析和验证实验,包括逆转录定量聚合酶链反应、western blot 和双荧光素酶报告基因检测,表明除了基因组扩增和转录激活外,KIF14 还受 microRNA(miR)-200c 的转录后调控。挽救实验进一步表明,miR-200c 表达的降低可促进 KIF14 发挥其促增殖作用。miR-200c 的表达与 CRC 标本中的 KIF14 呈负相关。综上所述,本研究结果表明 KIF14 在结直肠肿瘤发生中具有致癌作用,同时也揭示了调节 KIF14 过表达的复杂调控机制,可为开发 CRC 患者的新型治疗方法提供思路。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d82/6192758/2906f169e21f/IJO-53-05-1939-g00.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验